I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR
Market Cap: 732.8m EUR

Intercept Pharmaceuticals Inc
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Intercept Pharmaceuticals Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Change in Working Capital
-$25.3m
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$2.3B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
-31%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
27%
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
$10.4B
CAGR 3-Years
N/A
CAGR 5-Years
102%
CAGR 10-Years
20%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$811.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
$440.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
9%
No Stocks Found

Intercept Pharmaceuticals Inc
Glance View

Market Cap
732.5m EUR
Industry
Biotechnology

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

I4P Intrinsic Value
Not Available
I

See Also

What is Intercept Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-25.3m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Change in Working Capital amounts to -25.3m USD.

What is Intercept Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-23%

Back to Top